Do you want to read an article? Please log in or register.
Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens: A Cohort Study Using National Registry Data
Pulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Wolter DJ, Onchiri FM, Emerson J, Precit MR, Lee M, McNamara S, Nay L, Blackledge M, Uluer A, Orenstein DM, Mann M, Hoover W, Gibson RL, Burns JL, Hoffman LR, SCVSA study group.
doi: 10.1016/S2213-2600(19)30365-0.Visit the original publication at ncbi.nlm.nih.gov
Pulmonary Fibrosis
Respiratory rate in infants with cystic fibrosis throughout the first year of life and association with lung clearance index measured shortly after birth
J Cyst Fibros.
Korten I, Kieninger E, Yammine S, Cangiano G, Nyilas S, Anagnostopoulou P, Singer F, Kuehni CE, Regamey N, Frey U, Casaulta C, Spycher BD, Latzin P; SCILD; BILD study group
doi: 10.1016/j.jcf.2018.07.002.
Pulmonary Fibrosis
Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment
J Cyst Fibros.
Nagy B Jr, Bene Z, Fejes Z, Heltshe SL, Reid D, Ronan NJ, McCarthy Y, Smith D, Nagy A, Joseloff E, Balla G, Kappelmayer J, Macek M Jr, Bell SC, Plant BJ, Amaral MD, Balogh I
doi: 10.1016/j.jcf.2018.08.013.
RECOMMENDED
Bronchi
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
Lancet Respir Med.
Haworth CS, Bilton D, Chalmers JD, Davis AM, Froehlich J, Gonda I, Thompson B, Wanner A, O'Donnell AE
doi: 10.1016/S2213-2600(18)30427-2.
Initial acquisition and succession of the cystic fibrosis lung microbiome is associated with disease progression in infants and preschool children
PLoS Pathog.
Muhlebach MS, Zorn BT, Esther CR, Hatch JE, Murray CP, Turkovic L, Ranganathan SC, Boucher RC, Stick SM, Wolfgang MC
doi: 10.1371/
RECOMMENDED
Pulmonary Fibrosis
Lung function in children with cystic fibrosis in the USA and UK: a comparative longitudinal analysis of national registry data
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Thorax
Schlüter DK, Ostrenga JS, Carr SB, Fink AK, Faro A, Szczesniak RD, Keogh RH, Charman SC, Marshall BC, Goss CH, Taylor-Robinson D
doi: 10.1136/thoraxjnl-2021-216849
RECOMMENDED
Pulmonary Fibrosis
Average rate of lung function decline in adults with cystic fibrosis in the United Kingdom: Data from the UK CF registry
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros.
Caley L, Smith L, White H, Peckham DG
doi: 10.1016/j.jcf.2020.04.008.
RECOMMENDED
Pulmonary Fibrosis
Real-world use of ivacaftor in Canada: A retrospective analysis using the Canadian Cystic Fibrosis Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Cyst Fibros
Kawala CR, Ma X, Sykes J, Stanojevic S, Coriati A, Stephenson AL
doi: 10.1016/j.jcf.2021.03.008
RECOMMENDED
Pulmonary Fibrosis
Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros.
Nick JA, St Clair C, Jones MC, Lan L, Higgins M, VX12-770-113 Study Team.
doi: 10.1016/j.jcf.2019.09.013.